Source 1review2018Biomedicines
Toolkit/oncolytic viruses
oncolytic viruses
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Oncolytic viruses are described in this evidence set as viral platforms that can be rapidly engineered with CRISPR-Cas9 for cancer immunotherapeutic applications. The cited role is as an editable delivery harness within cancer therapy development.
Usefulness & Problems
Why this is useful
This platform is useful because the evidence indicates that CRISPR-Cas9 enables rapid engineering of oncolytic viruses for cancer immunotherapy. That positions oncolytic viruses as modifiable therapeutic carriers in oncology-focused development workflows.
Source:
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
Source:
CRISPR-Cas9 has shown an unprecedented clinical potential to discover novel targets for cancer therapy and to dissect chemical-genetic interactions, providing insight into how tumours respond to drug treatment.
Source:
Because of its high efficiency and accuracy, the CRISPR-Cas9 genome editing technique has recently emerged as a potentially powerful tool in the arsenal of cancer therapy.
Problem solved
The specific problem addressed here is the need to rapidly engineer viral cancer therapy platforms for immunotherapeutic applications. The evidence does not provide further detail on which viral features, payloads, or tumor-selective properties are edited.
Source:
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
Source:
CRISPR-Cas9 has shown an unprecedented clinical potential to discover novel targets for cancer therapy and to dissect chemical-genetic interactions, providing insight into how tumours respond to drug treatment.
Source:
Because of its high efficiency and accuracy, the CRISPR-Cas9 genome editing technique has recently emerged as a potentially powerful tool in the arsenal of cancer therapy.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
genome editingTechniques
No technique tags yet.
Target processes
editingImplementation Constraints
The only implementation detail supported here is the use of CRISPR-Cas9 to engineer oncolytic viruses. The evidence does not specify construct architecture, host cells for virus production, genome editing workflow, or manufacturing considerations.
The evidence is limited to a high-level application statement and does not specify viral species, edited loci, delivery strategy, or therapeutic efficacy. It also does not document independent replication, clinical validation, or safety characteristics for the engineered oncolytic viruses.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
CRISPR-Cas9 can be used to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be used to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be used to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be used to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be used to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be used to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be used to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 has clinical potential for discovering novel targets for cancer therapy and dissecting chemical-genetic interactions related to tumor drug response.
CRISPR-Cas9 has shown an unprecedented clinical potential to discover novel targets for cancer therapy and to dissect chemical-genetic interactions, providing insight into how tumours respond to drug treatment.
CRISPR-Cas9 is presented as a potentially powerful tool for cancer therapy.
Because of its high efficiency and accuracy, the CRISPR-Cas9 genome editing technique has recently emerged as a potentially powerful tool in the arsenal of cancer therapy.
Important considerations and major challenges remain to be addressed before CRISPR/Cas9 can be clinically translated for cancer, a complex and polygenic disease.
In this review, we discuss important considerations for the use of CRISPR/Cas9 in therapeutic settings and major challenges that will need to be addressed prior to its clinical translation for a complex and polygenic disease such as cancer.
Approval Evidence
1 source1 linked approval claimfirst-pass slug oncolytic-viruses
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
Source:
application scopesupports
CRISPR-Cas9 can be used to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications.
Source:
Comparisons
Source-backed strengths
A stated strength is rapid engineering of oncolytic viruses using CRISPR-Cas9 in the context of cancer immunotherapy. No quantitative performance data, in vivo outcomes, or comparative benchmarks are provided in the supplied evidence.
Ranked Citations
- 1.